Clinical symptom responses to atypical antipsychotic medications in Alzheimer's disease: Phase 1 outcomes from the CATIE-AD effectiveness trial

American Journal of Psychiatry

Volumn 165, Issue 7, 2008, Pages 844-854

  Sultzer, David L ^a   Davis, Sonia M ^b   Tariot, Pierre N ^b   Dagerman, Karen S ^b   Lebowitz, Barry D ^b   Lyketsos, Constantine G ^b   Rosenheck, Robert A ^b   Hsiao, John K ^b   Lieberman, Jeffrey A ^b   Schneider, Lon S ^b  

^a Psychiatry   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE;

AGED; AGGRESSION; AGITATION; ALZHEIMER DISEASE; ANGER; ARTICLE; BRIEF PSYCHIATRIC RATING SCALE; CLINICAL GLOBAL IMPRESSION SCALE; CLINICAL TRIAL; COGNITION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DRUG CAPSULE; DRUG EFFICACY; DRUG MEGADOSE; FEMALE; FUNCTIONAL ASSESSMENT; HOSTILITY; HUMAN; LOW DRUG DOSE; MAJOR CLINICAL STUDY; MALE; MENTAL DISEASE; MULTICENTER STUDY; NEEDS ASSESSMENT; PARANOIA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; PSYCHOSIS; QUALITY OF LIFE; RANDOMIZED CONTROLLED TRIAL; STATISTICAL SIGNIFICANCE; TREATMENT DURATION; TREATMENT OUTCOME; TREATMENT RESPONSE;

ACTIVITIES OF DAILY LIVING; AGED; AGGRESSION; ALZHEIMER DISEASE; ANTIPSYCHOTIC AGENTS; BENZODIAZEPINES; BRIEF PSYCHIATRIC RATING SCALE; COGNITION DISORDERS; DIBENZOTHIAZEPINES; FEMALE; HUMANS; MALE; NEUROPSYCHOLOGICAL TESTS; PSYCHOMOTOR AGITATION; PSYCHOTIC DISORDERS; QUALITY OF LIFE; QUESTIONNAIRES; RISPERIDONE;

EID: 46749095495     PISSN: 0002953X     EISSN: None     Source Type: Journal    
DOI: 10.1176/appi.ajp.2008.07111779     Document Type: Article

References (34)

1. Lyketsos CG, Steinberg M, Tschanz JT, Norton MC, Steffens DC, Breitner JCS: Mental and behavioral disturbances in dementia: findings from the Cache County Study on Memory in Aging. Am J Psychiatry 2000; 157:708-714
2. Ropacki SA, Jeste DV: Epidemiology of and risk factors for psychosis of Alzheimer's disease: a review of 55 studies published from 1990 to 2003. Am J Psychiatry 2005; 162:2022-2030
3. Lopez OL, Becker JT, Sweet RA, Klunk W, Kaufer DI, Saxton J, Habeych M, DeKosky ST: Psychiatric symptoms vary with the severity of dementia in probable Alzheimer's disease. J Neuropsychiatry Clin Neurosci 2003; 15:346-353
4. Craig D, Mirakhur A, Hart DJ, McIlroy SP, Passmore AP: A cross sectional study of neuropsychiatric symptoms in 435 patients with Alzheimer's disease. Am J Geriatr Psychiatry 2005; 13:460-468
5. Schulz R, O'Brien AT, Bookwala J, Fleissner K: Psychiatric and physical morbidity effects of dementia caregiving: prevalence, correlates and causes. Gerontologist 1995; 35:771-791
6. Magni E, Binetti G, Bianchetti A, Trabucchi M: Risk of mortality and institutionalization in demented patients with delusions. J Geriatr Psychiatry Neurol 1996; 9:123-126
7. Stern Y, Tang M-X, Albert MS, Brandt J, Jacobs DM, Bell K, Marder K, Sano M, Devanand D, Albert SM, Bylsma F, Tsai W-Y: Predicting time to nursing home care and death in individuals with Alzheimer disease. JAMA 1997; 227:806-812
8. Murman DL, Chen Q, Powell MC, Kuo SB, Bradley CJ, Colenda CC: The incremental direct costs associated with behavioral symptoms in Alzheimer's disease. Neurology 2002; 59:1721-1729
9. Ryu S, Katoma C, Rive B, Livingston G: Persistence of and changes in neuropsychiatric symptoms in Alzheimer's disease over 6 months. Am J Geriatr Psychiatry 2005; 13:976-983
10. Livingston G, Johnston K, Katona C, Paton J, Lyketsos CG: Systematic review of psychological approaches to the management of neuropsychiatric symptoms of dementia. Am J Psychiatry 2005; 162:1996-2021
11. Ayalon L, Gum AM, Feliciano L, Arean PA: Effectiveness of nonpharmacological interventions for the management of neuropsychiatric symptoms in patients with dementia. Arch Intern Med 2006; 166:2182-2188
12. Trinh NH, Hoblyn J, Mohanty S, Yaffe K: Efficacy of cholinesterase inhibitors in the treatment of neuropsychiatric symptoms and functional impairment in Alzheimer disease: a meta-analysis. JAMA 2003; 289:210-216
13. Cummings JL, Schneider E, Tariot PN, Graham SM: Behavioral effects of memantine in Alzheimer disease patients receiving donepezil treatment. Neurology 2006; 67:57-63
14. Howard RJ, Juszczak E, Ballard CG, Bentham P, Brown RG, Bullock R, Burns AS, Holmes C, Jacoby R, Johnson T, Knapp MJ, Lindesay J, O'Brien JT, Wilcock GK, Katona C, Jones RW, DeCesare J, Rodger M, CALM-AD Trial Group: Donepezil for the treatment of agitation in Alzheimer's disease. N Engl J Med 2007; 357:1382-1392
15. Schneider LS, Dagerman K, Insel PS: Efficacy and adverse effects of atypical antipsychotics for dementia: meta-analysis of randomized, placebo-controlled trials. Am J Geriatr Psychiatry 2006; 14:190-209
16. Schneider LS, Ismail MS, Dagerman K, Davis S, Olin J, McManus D, Pfeiffer E, Ryan JM, Sultzer DL, Tariot PN: Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer's disease trial. Schizophr Bull 2003; 29:57-72
17. Schneider LS, Tariot PN, Dagerman KS, Davis SM, Hsiao JK, Ismail S, Lebowitz BD, Lyketsos CG, Ryan JM, Stroup TS, Sultzer DL, Weintraub D, Lieberman JA: Effectiveness of atypical antipsychotic drugs in patients with Alzheimer's disease. N Engl J Med 2006; 355:1525-1538
18. Schneider LS, Tariot PN, Lyketsos CG, Dagerman KS, Davis KL, Davis S, Hsiao JK, Jeste DV, Katz IR, Olin JT, Pollock BG, Rabins PV, Rosenheck RA, Small GW, Lebowitz B, Lieberman JA: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness (CATIE): Alzheimer disease trial methodology. Am J Geriatr Psychiatry 2001; 9:346-360
19. McKhann G, Drachman D, Folstein M, Katzman R, Price D, Stadlan EM: Clinical diagnosis of Alzheimer's disease: report of the NINCDS-ADRDA Work Group under the auspices of the Department of Health and Human Services Task Force on Alzheimer's Disease. Neurology 1984; 34:939-944
20. Folstein M, Folstein S, McHugh P: "Mini-Mental State": a practical method for grading the cognitive state of patients for the clinician. J Psychiatr Res 1975; 12:189-198
21. Overall JE, Gorham DR: The Brief Psychiatric Rating Scale (BPRS): recent developments in ascertainment and scaling. Psychopharmacol Bull 1988; 24:97-99
22. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J: The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 1994; 44:2308-2314
23. Overall JE, Beller SA: The Brief Psychiatric Rating Scale (BPRS) in geropsychiatric research, I: factor structure on an inpatient unit. J Gerontol 1984; 39:187-193
24. Alexopoulos GS, Abrams RC, Young RC, Shamoian CA: Cornell Scale for Depression in Dementia. Biol Psychiatry 1988; 23:271-284
25. Schneider LS, Olin JT, Clark CM, Morris JC, Reisberg B, Schmitt FA, Grundman M, Thomas RG, Ferris SH: Validity and reliability of the Alzheimer's Disease Cooperative Study - Clinical Global Impression of Change. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S22-S32
26. Rosen WG, Mohs RC, Davis KL: A new rating scale for Alzheimer's disease. Am J Psychiatry 1984; 141:1356-1364
27. Galasko D, Bennett D, Sano M, Ernesto C, Thomas R, Grundman M, Ferris S: An inventory to assess activities of daily living for clinical trials in Alzheimer's disease: the Alzheimer's Disease Cooperative Study. Alzheimer Dis Assoc Disord 1997; 11(suppl 2):S33-S39
28. Stern Y, Albert SM, Sano M, Richards M, Miller L, Folstein M, Albert M, Bylsma F, Lafleche G: Assessing patient dependence in Alzheimer's disease. J Gerontol 1994; 49:M216-M222
29. Davis KL, Marin DB, Kane R, Patrick D, Peskind ER, Raskind MA, Puder KL: The Caregiver Activity Survey (CAS): development and validation of a new measure for caregivers of persons with Alzheimer's disease. Int J Geriatr Psychiatry 1997; 12:978-988
30. Rabins PV, Kasper JD, Kleinman L, Black BS, Patrick DL: Concepts and methods in the development of the ADRQL: an instrument for assessing health-related quality of life in persons with Alzheimer disease. J Ment Health Aging 1999; 5:33-48
31. Hochberg YA: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988; 75:800-802
32. Ismail MS, Dagerman K, Tariot PN, Abbott S, Kavanagh S, Schneider LS: National Institute of Mental Health Clinical Antipsychotic Trials of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD): baseline characteristics. Curr Alzheimer Res 2007; 4:325-335
33. Sultzer DL, Brown CV, Mandelkern MA, Mahler ME, Mendez MF, Chen ST, Cummings JL: Delusional thoughts and regional frontal/ temporal cortex metabolism in Alzheimer's disease. Am J Psychiatry 2003; 160:341-349
34. Rosenheck RA, Leslie DL, Sindelar J, Miller EA, Tariot PN, Dagerman KS, Davis S, Lebowitz BD, Rabins P, Hsiao JK, Lieberman JA, Schneider LS, Clinical Antipsychotic Trial of Intervention Effectiveness-Alzheimer's Disease (CATIE-AD) investigators: A randomized trial of the cost-effectiveness of second generation antipsychotics and placebo in the treatment of psychosis and aggression in Alzheimer's disease. Arch Gen Psychiatry 2007; 64:1259-1268